Brief: United Laboratories International Says Approval For Clinical Trial By NMPA Of China
08/09/2023 15:49
Sept 8 (Reuters) - United Laboratories International
Holdings Ltd 3933.HK :
* APPROVAL FOR CLINICAL TRIAL OF UBT251 INJECTION ON
INDICATION OF
NON-ALCOHOLIC FATTY LIVER DISEASE BY NMPA OF CHINA
Further company coverage: 3933.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on United Laboratories International Holdings
See all newsBrief: United Laboratories International Receives Milestone Payment From Novo
Brief: United Laboratories International Says NMPA Accepts Insulin Degludec And Liraglutide Injection Marketing Registration Application
Brief: United Laboratories International Posts HY Profit Attributable RMB 347.6 Million
China's United Laboratories half-year profit drops 82%
Brief: United Laboratories International Expects HY Net Profit RMB 340 Million